BioXcel Therapeutics (BTAI) Total Non-Current Liabilities (2022 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Total Non-Current Liabilities of $132.9 million for Q1 2026, up 5.89% year-over-year from $125.5 million in Q1 2025, and down 4.14% quarter-over-quarter from $138.6 million in Q4 2025.
BioXcel Therapeutics (BTAI) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
BioXcel Therapeutics' Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $132.9 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 5.89% year-over-year to $132.9 million; the TTM figure through Mar 2026 stood at $132.9 million (up 5.89% YoY), while the FY2025 annual figure was $138.6 million, up 11.04% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $132.9 million, down from $138.6 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $139.0 million in Q3 2023, with the low at $82.0 million in Q2 2022.
- The 5-year median for Total Non-Current Liabilities is $130.1 million (2024), against an average of $126.6 million.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities surged 61.19% in 2023, then retreated 6.38% in 2024.
- BioXcel Therapeutics' Total Non-Current Liabilities stood at $126.7 million in 2022, then rose by 1.24% to $128.3 million in 2023, then fell by 2.73% to $124.8 million in 2024, then rose by 11.04% to $138.6 million in 2025, then declined by 4.14% to $132.9 million in 2026.
- Business Quant data shows BTAI's Total Non-Current Liabilities at $132.9 million in Q1 2026, $138.6 million in Q4 2025, and $130.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 334.00 Mn |
| 10 | BioXcel Therapeutics | 24.29 Mn | 24.29 Mn | 160,000.00 | 137.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 137.15 Mn |
| Mar 31, 2026 | 132.85 Mn |
| Dec 31, 2025 | 138.59 Mn |
| Sep 30, 2025 | 130.11 Mn |
| Jun 30, 2025 | 130.85 Mn |
| Mar 31, 2025 | 125.46 Mn |
| Dec 31, 2024 | 124.81 Mn |
| Sep 30, 2024 | 130.16 Mn |
| Jun 30, 2024 | 130.55 Mn |
| Mar 31, 2024 | 133.46 Mn |
| Dec 31, 2023 | 128.31 Mn |
| Sep 30, 2023 | 139.03 Mn |
| Jun 30, 2023 | 132.21 Mn |
| Mar 31, 2023 | 124.52 Mn |
| Dec 31, 2022 | 126.74 Mn |
| Sep 30, 2022 | 115.94 Mn |
| Jun 30, 2022 | 82.02 Mn |